Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Adicon Holdings Limited (9860.HK): Continuous growth in Core Operations, Consistent Profitability Enhancement 2023-09-01 21:30
Innovac Therapeutics Completes $18 million Series Pre-A Financing To Fund the Development of Its lead Programs and Manufacturing Capabilities 2023-09-01 20:08
Peijia Medical Announces 2023 Interim Results 2023-09-01 19:00
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023 2023-08-31 15:15
Tycoon Group Announces 2023 Interim Results 2023-08-31 13:28
Zylox-Tonbridge's ZENFlow Tiger™ LD PTA Dilatation Catheter Receives ANVISA Marketing Approval 2023-08-31 11:31
LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony' 2023-08-31 09:00
Jacobio Pharma Announces 2023 Interim Results 2023-08-30 21:45
GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community 2023-08-30 16:05
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis 2023-08-30 14:19
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC 2023-08-30 11:00
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure 2023-08-30 10:53
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF 2023-08-30 08:03
Epigenic Therapeutics Announces $32 Million in Series A Funding to Bring Breakthrough Epigenome Medicine to Clinical Development 2023-08-30 08:00
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023 2023-08-30 00:02
Datasea Announces Strategic Partnership with Sales and Marketing Firm for the Launch of Intelligent Acoustic Skin Repair Robot 2023-08-29 21:57
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC 2023-08-29 20:00
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference 2023-08-28 20:00
Harbour BioMed Announces 2023 Interim Results 2023-08-28 17:08
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors 2023-08-28 16:30
1 63 64 65 66 67 431